A 46-year-old cisgender woman with HIV presents for a routine follow-up visit. She started taking efavirenz-tenofovir DF-emtricitabine 11 years ago when her baseline HIV RNA was 34,300 copies/mL. A baseline drug resistance genotype showed no mutations. On this antiretroviral regimen, she has consistently suppressed HIV RNA levels. Recently, she has been struggling with insomnia and depression. A switch in the antiretroviral regimen is recommended. She had a friend who gained weight after taking bictegravir-tenofovir alafenamide-emtricitabine, and she does not want to take that regimen or anything similar to it. Thus, a switch to rilpivirine-tenofovir alafenamide-emtricitabine is being considered.